Back to Search
Start Over
Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial
- Source :
- The British journal of ophthalmology. 93(4)
- Publication Year :
- 2008
-
Abstract
- The aim of the study was to evaluate functional and anatomical changes after intravitreal bevacizumab (Avastin) in eyes with persistent macular oedema secondary to branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO).Twenty-nine consecutive eyes with macular oedema secondary to BRVO (21 eyes) or CRVO (eight eyes) were included in a prospective clinical trial. Eyes were treated with three initial intravitreal bevacizumab injections of 1 mg at a monthly interval. Retreatment was based on central retinal thickness (CRT) based on optical coherence tomography. If continuous injections were indicated up to month 6, the dose was increased to 2.5 mg.After 12 months of follow-up, mean visual acuity increased from 50 letters (20/100) at baseline to 66 letters (20/50(+1); +16 letters; p0.001) at month 12 and CRT decreased from 558 mum at baseline to 309 mum at month 12 (-249 mum; p0.001). Patients received a mean of eight out of 13 possible injections. No drug-related systemic or ocular side effects following intravitreal bevacizumab treatment were observed. Fluorescein angiography revealed no progression of avascular areas.Intravitreal therapy using bevacizumab appears to be a safe and effective treatment in patients with macular oedema secondary to retinal vein occlusion. However, the main limitations of this treatment modality are its short-term effectiveness and high recurrence rate.
- Subjects :
- Adult
Male
medicine.medical_specialty
Visual acuity
Retinal Vein
genetic structures
Bevacizumab
Visual Acuity
Angiogenesis Inhibitors
Antibodies, Monoclonal, Humanized
Drug Administration Schedule
Macular Edema
Injections
Cellular and Molecular Neuroscience
chemistry.chemical_compound
Central retinal vein occlusion
Occlusion
Retinal Vein Occlusion
Medicine
Humans
Prospective Studies
Aged
Aged, 80 and over
business.industry
Antibodies, Monoclonal
Retinal
Middle Aged
medicine.disease
eye diseases
Sensory Systems
Surgery
Vitreous Body
Ophthalmology
Treatment Outcome
chemistry
Branch retinal vein occlusion
Female
sense organs
medicine.symptom
business
medicine.drug
Retinopathy
Follow-Up Studies
Subjects
Details
- ISSN :
- 14682079
- Volume :
- 93
- Issue :
- 4
- Database :
- OpenAIRE
- Journal :
- The British journal of ophthalmology
- Accession number :
- edsair.doi.dedup.....82ffa3ba28557bdb9b9b7f38a0187184